#GSK has continued its drive to bulk up its #pipeline, taking global rights to a #Tcellengager (TCE) for #multiplemyeloma, developed by China's #ChimagenBiosciences, for up to $750 million.
@pharmaphorum.bsky.social@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#GSK has continued its drive to bulk up its #pipeline, taking global rights to a #Tcellengager (TCE) for #multiplemyeloma, developed by China's #ChimagenBiosciences, for up to $750 million.